257 related articles for article (PubMed ID: 27127882)
1. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
Xia Y; Huang CC; Dittmar R; Du M; Wang Y; Liu H; Shenoy N; Wang L; Kohli M
Oncotarget; 2016 Jun; 7(24):35818-35831. PubMed ID: 27127882
[TBL] [Abstract][Full Text] [Related]
2. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract][Full Text] [Related]
3. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
4. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
6. A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors.
Qu X; Randhawa G; Friedman C; Kurland BF; Glaskova L; Coleman I; Mostaghel E; Higano CS; Porter C; Vessella R; Nelson PS; Fang M
PLoS One; 2013; 8(9):e74671. PubMed ID: 24098661
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Copy Number Variation in Urine: c-Myc Evaluation Using a Real-Time PCR Approach.
Casadio V; Martignano F; Gunelli R; Salvi S
Methods Mol Biol; 2021; 2292():49-56. PubMed ID: 33651351
[TBL] [Abstract][Full Text] [Related]
8. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
9. Studying Copy Number Variations in Cell-Free DNA: The Example of AR in Prostate Cancer.
Salvi S; Casadio V
Methods Mol Biol; 2019; 1909():95-103. PubMed ID: 30580425
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
11. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
[TBL] [Abstract][Full Text] [Related]
12. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
[TBL] [Abstract][Full Text] [Related]
13. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer.
Attard G; Swennenhuis JF; Olmos D; Reid AH; Vickers E; A'Hern R; Levink R; Coumans F; Moreira J; Riisnaes R; Oommen NB; Hawche G; Jameson C; Thompson E; Sipkema R; Carden CP; Parker C; Dearnaley D; Kaye SB; Cooper CS; Molina A; Cox ME; Terstappen LW; de Bono JS
Cancer Res; 2009 Apr; 69(7):2912-8. PubMed ID: 19339269
[TBL] [Abstract][Full Text] [Related]
14. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity.
Choucair K; Ejdelman J; Brimo F; Aprikian A; Chevalier S; Lapointe J
BMC Cancer; 2012 Nov; 12():543. PubMed ID: 23171135
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
16. Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.
Friedlander TW; Roy R; Tomlins SA; Ngo VT; Kobayashi Y; Azameera A; Rubin MA; Pienta KJ; Chinnaiyan A; Ittmann MM; Ryan CJ; Paris PL
Cancer Res; 2012 Feb; 72(3):616-25. PubMed ID: 22158653
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T; Mizuno K; Yamasaki T; Miyazaki Y; Makino Y; Okasho K; Li X; Utsunomiya N; Goto T; Kobayashi T; Terada N; Inoue T; Kamba T; Fujimoto A; Ogawa O; Akamatsu S
Sci Rep; 2019 Mar; 9(1):4030. PubMed ID: 30858508
[TBL] [Abstract][Full Text] [Related]
18. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
20. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]